- Home
- NYXH vs EYPT Comparison
NYXH vs EYPT Comparison
Compare NYXH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYXH
- EYPT
- Stock Information
- Founded
- NYXH 2009
- EYPT 1987
- Country
- NYXH Belgium
- EYPT United States
- Employees
- NYXH N/A
- EYPT N/A
- Industry
- NYXH Medical/Dental Instruments
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- NYXH Health Care
- EYPT Industrials
- Exchange
- NYXH Nasdaq
- EYPT Nasdaq
- Market Cap
- NYXH 394.1M
- EYPT 427.9M
- IPO Year
- NYXH 2021
- EYPT 2005
- Fundamental
- Price
- NYXH $6.50
- EYPT $5.37
- Analyst Decision
- NYXH Strong Buy
- EYPT Strong Buy
- Analyst Count
- NYXH 4
- EYPT 8
- Target Price
- NYXH $14.75
- EYPT $25.71
- AVG Volume (30 Days)
- NYXH 86.3K
- EYPT 734.5K
- Earning Date
- NYXH 05-13-2025
- EYPT 03-05-2025
- Dividend Yield
- NYXH N/A
- EYPT N/A
- EPS Growth
- NYXH N/A
- EYPT N/A
- EPS
- NYXH N/A
- EYPT N/A
- Revenue
- NYXH $4,680,609.00
- EYPT $43,273,000.00
- Revenue This Year
- NYXH $504.18
- EYPT N/A
- Revenue Next Year
- NYXH $149.52
- EYPT N/A
- P/E Ratio
- NYXH N/A
- EYPT N/A
- Revenue Growth
- NYXH 3.98
- EYPT N/A
- 52 Week Low
- NYXH $6.30
- EYPT $4.92
- 52 Week High
- NYXH $13.50
- EYPT $23.65
- Technical
- Relative Strength Index (RSI)
- NYXH 21.44
- EYPT 35.80
- Support Level
- NYXH $10.26
- EYPT $5.87
- Resistance Level
- NYXH $11.87
- EYPT $6.69
- Average True Range (ATR)
- NYXH 0.75
- EYPT 0.40
- MACD
- NYXH -0.48
- EYPT -0.11
- Stochastic Oscillator
- NYXH 3.59
- EYPT 21.03
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.